G1 Therapeutics to Present at 2024 ASCO Meeting

G1 Therapeutics, Inc. (Nasdaq: GTHX), an oncology-focused biopharmaceutical company, has announced the mature results of its Phase 2 trial investigating the effects of trilaciclib combined with sacituzumab govitecan (SG) on overall survival (OS) and tolerability in patients with metastatic triple-negative breast cancer (mTNBC). These findings will be presented at the 2024 American Society of Clinical Oncology (ASCO) Meeting, scheduled to be held from May 31 to June 4 in Chicago, Illinois. Attendees can view the results at a poster session on June 2, and a copy will be available on the G1 Therapeutics website afterward.

The abstract released by ASCO today includes the initial Phase 2 trial results disclosed by G1 Therapeutics in January 2024. The upcoming poster presentation will offer an updated view of the trial's mature results, highlighting the continued positive impact of trilaciclib in combination with SG compared to SG alone, based on historical data from the ASCENT trial.

Poster Presentation Details:
- Title: Trilaciclib Combined with Sacituzumab Govitecan (SG) in Metastatic Triple Negative Breast Cancer (mTNBC): Updated Phase 2 Safety and Efficacy Results
- Authors: Seneviratne, L. et al.
- Poster Number: 1091
- Session: Breast Cancer-Metastatic
- Date and Time: Sunday, June 2, 2024, from 9:00 AM to 12:00 PM CDT

About G1 Therapeutics:
G1 Therapeutics, Inc., based in Research Triangle Park, N.C., is dedicated to developing innovative cancer therapies aimed at improving patient outcomes. The company's flagship product, COSELA® (trilaciclib), is already on the market, and G1 Therapeutics continues to explore the potential of combining its therapies with cytotoxic treatments and immunotherapies. Their current research focuses on areas with significant unmet medical needs, such as triple-negative breast cancer and extensive-stage small cell lung cancer. G1 Therapeutics strives to become a leader in providing groundbreaking treatments for cancer patients.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!